Clinical trial
Abatacept as GVHD Prophylaxis Phase 2
NCT01743131 · Boston Children's Hospital, Other · Completed
Key facts
| NCT number | NCT01743131 |
|---|---|
| Title | Abatacept as GVHD Prophylaxis Phase 2 |
| Official title | Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial |
| Lead sponsor | Boston Children's Hospital, Other |
| Collaborators | FDA Office of Orphan Products Development U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft vs Host Disease, Malignancy |
| Intervention type | Drug |
| Interventions | Abatacept, placebo |
| Enrollment | 186 |
| Start date | Feb 1, 2013 |
| Primary completion | Jun 30, 2018 |
| Completion | Mar 30, 2024 |
| First posted | Dec 6, 2012 |
| Last update posted | Dec 11, 2025 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: